AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the medical technology sector, has announced the upcoming release of its financial results for the first quarter of fiscal year 2026, scheduled for October 2, 2025. This report will be made public prior to the market opening on that date. For investors and stakeholders interested in the company’s performance, AngioDynamics will host a conference call at 8:00 AM ET to discuss these results in detail.

To join the conference call, participants can dial 1-877-407-0784 for domestic calls or +1-201-689-8560 for international access. Additionally, the conference call will be available as a webcast, which can be accessed through the "Investors" section of AngioDynamics' official website at www.angiodynamics.com. Following the call, a replay will be available approximately one hour later on the same site, and the recording can be accessed until October 9, 2025, at 11:59 PM ET by dialing 1-844-512-2921 domestically or +1-412-317-6671 internationally, using the passcode 13755707.

AngioDynamics is dedicated to addressing critical healthcare challenges by developing innovative medical technologies aimed at restoring healthy blood flow in the vascular system and providing enhanced treatment options for cancer patients. As the company continues to expand its footprint in fast-growing healthcare markets, its commitment to improving patient quality of life remains at the forefront of its mission. Investors and analysts will be keenly observing the financial outcomes of this quarter to assess the company's momentum and strategic direction. For further inquiries, Stephen Trowbridge, Executive Vice President & CFO, is available at (518) 795-1408.

As AngioDynamics, Inc. (NASDAQ: ANGO) prepares to report its fiscal 2026 first-quarter results on October 2, 2025, investors should closely examine several key aspects of the company’s financials and market position. AngioDynamics specializes in transformative medical technologies that aim to enhance vascular health and cancer treatment, catering to an ever-expanding healthcare market.

Ahead of this earnings release, it is essential to consider the potential impact of recent industry trends. With a growing emphasis on innovative medical solutions and an aging population, AngioDynamics is well-positioned to capitalize on heightened demand for advanced treatment options. Investors may find it useful to look at recent advancements in the company’s product offerings, particularly in minimally invasive treatments, which are increasingly favored in both oncology and vascular applications.

Market analysts will likely focus on revenue growth, margins, and guidance provided for future quarters. Notably, if AngioDynamics showcases continued growth in sales, particularly in high-margin segments, it could bolster investor confidence and potentially drive stock price appreciation. Alternatively, any significant discrepancies from analyst expectations could lead to market volatility.

The scheduled conference call at 8:00 AM ET will be a critical opportunity for management to clarify results, address investor concerns, and articulate the growth strategy moving forward. Listening in on this call can provide valuable insights into the company’s operational efficiency and reaffirmation of its market vision.

Investors should also monitor the broader healthcare market landscape, especially as developments in regulatory approvals and reimbursement policies can play a pivotal role in shaping AngioDynamics' performance. In this context, maintaining a balanced perspective while considering potential risks will be crucial as the company heads into its earnings announcement. Analyzing key metrics and emerging trends can empower informed decision-making for stakeholders in the coming weeks.